Coherus Oncology, Inc.
CHRS
Positions held
Your positionsCHRS isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $165.32M | Enterprise value | $114.19M | Trailing P/E | — | Forward P/E | -1.70 |
| PEG | — | Price / book | 2.72 | Beta | 0.99 | Dividend yield | 0.00% |
| Revenue growth | 39.5% | Earnings growth | — | Gross margin | 69.0% | Operating margin | -2.3% |
| Profit margin | -2.6% | ROE | -1.8% | ROA | -30.5% | Debt / equity | 0.89 |
| Current ratio | 1.77 | Free cash flow | -$160.15M | Analyst recommendation | none | Mean target | $7.75 |
| 52w high | $2.62 | 52w low | $0.97 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $14.3M | $12.3M | $12.7M | $11.6M | $10.3M |
| Op margin | -226.0% | -293.7% | -359.9% | -383.1% | -443.6% |
| Net income | -$20.6M | -$38.3M | -$37.6M | -$35.5M | $298M |
| Gross margin | 70.4% | 69.0% | 68.3% | 67.8% | 66.9% |
| Gross profit | $10.1M | $8.5M | $8.7M | $7.8M | $6.9M |
| Operating income | -$32.3M | -$36.2M | -$45.9M | -$44.3M | -$45.5M |
- Revenue +16% vs prior quarter ($14M vs $12M).
- Gross margin 70.4% (was 69% prior quarter).
- Operating margin expanded to -226%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $42.2M | $26.4M | $257M | $211M | — |
| Op margin | -429.5% | -756.6% | -79.0% | -121.7% | — |
| Net income | $168M | $28.5M | -$238M | -$292M | — |
| Gross margin | 67.2% | 66.9% | 38.2% | 66.8% | — |
| Gross profit | $28.4M | $17.7M | $98.3M | $141M | — |
| Operating income | -$181M | -$200M | -$203M | -$257M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-23 · Coherus Oncology Starts Process to Sell Remaining Biosimilar Assets
2026-09-23 · Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
2026-08-31 · Coherus to Participate in Upcoming Investor Conferences
2026-08-17 · Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
2026-08-13 · Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript
2026-08-06 · Coherus Oncology, Inc. Q2 2026 Earnings Call Summary
2026-08-06 · Coherus Oncology Inc (CHRS) (Q2 2026) Earnings Call Highlights: LOQTORZI Growth and Pipeline ...
2026-08-06 · Coherus Oncology Q2 Earnings Call Highlights
2026-08-05 · Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates
2026-08-05 · Coherus Oncology: Q2 Earnings Snapshot
2026-08-05 · Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-22 · Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026
Price (daily)
Full chart · RSI · MACD · patterns